Compare Regeneron Pharmaceuticals Inc (REGN) vs Tapestry, Inc. (TPR) Price & Performance

Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.

The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.

TPR trades at $115.82, down 0.78% today, with a bearish technical signal but strong analyst support (73% buy ratings). The company shows robust profitability with 77.82% gross margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights international growth in China and Europe, though the stock faces headwinds from tariff risks and Kate Spade execution challenges.

Outlook remains positive with a $174.64 consensus price target suggesting 51% upside, supported by fiscal 2027 margin expansion targets. Key risks include tariff pressures, premium valuation (P/E 15.6), and recent net cash outflows. The stock presents a growth opportunity if international momentum continues and margin targets are achieved.